Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Cancer Research UK Phase I/IIa Trial of AT9283 (A Selective Inhibitor of Aurora Kinases) Given Over 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents Aged 6 Months to 18 Years With Relapsed and Refractory Acute Leukemia
Authors not listed
Cancer Research UK · 2011
Abstract
RATIONALE: AT9283 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I/IIa clinical trial is studying the side effects and best dose of AT9283 in treating young patients with relapsed or refractory acute leukemia.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Anonymous. (2011). A Cancer Research UK Phase I/IIa Trial of AT9283 (A Selective Inhibitor of Aurora Kinases) Given Over 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents Aged 6 Months to 18 Years With Relapsed and Refractory Acute Leukemia. <em>Cancer Research UK</em>. https://clinicaltrials.gov/study/NCT01431664
Vancouver
Anonymous. A Cancer Research UK Phase I/IIa Trial of AT9283 (A Selective Inhibitor of Aurora Kinases) Given Over 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents Aged 6 Months to 18 Years With Relapsed and Refractory Acute Leukemia. Cancer Research UK. 2011.
BibTeX
@misc{anon2011ACance,
title = {A Cancer Research UK Phase I/IIa Trial of AT9283 (A Selective Inhibitor of Aurora Kinases) Given Over 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents Aged 6 Months to 18 Years With Relapsed and Refractory Acute Leukemia},
author = {Anonymous},
journal = {Cancer Research UK},
year = {2011},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
2018
Open access · OA
Is Taurine a Pharmaconutrient?
Albert Einstein College of Medicine 2013
Open access · US-GOV
A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML)
Institut Bergonié 2008
Open access · US-GOV
Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial With Emphasis on Geriatric Assessment and Quality of Life
Journal of Geriatric Oncology 2019
Preprint · OA
Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia
Roswell Park Cancer Institute 2006
Open access · US-GOV
Phase II Study of Erlotinib (Tarceva®) and Radiotherapy for Elderly Patients With Esophageal Carcinoma
German CLL Study Group 2003
Open access · US-GOV